bempedoic acid Side Effects
Also known as: Nexletol
Analysis of 2,157 adverse event reports submitted to the FDA from 2018 to 2025.
Total Reports
2,157
Death-Related
16
0.7% of reports
Hospitalizations
188
8.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 16 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 13 |
| OFF LABEL USE | 2 |
| PAIN IN EXTREMITY | 2 |
| ASTHENIA | 1 |
| BRONCHIAL CARCINOMA | 1 |
| CARDIAC FAILURE | 1 |
| CARDIOVASCULAR DISORDER | 1 |
| CEREBRAL HAEMORRHAGE | 1 |
| CONSTIPATION | 1 |
| CYTOPENIA | 1 |
| DEHYDRATION | 1 |
| DIARRHOEA | 1 |
| DISEASE PROGRESSION | 1 |
| DISTURBANCE IN ATTENTION | 1 |
| DRUG INTERACTION | 1 |
| FALL | 1 |
| FATIGUE | 1 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1 |
| HEAD INJURY | 1 |
| HODGKIN^S DISEASE | 1 |
Reactions in Hospitalization Reports
Top reactions in 188 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| MYALGIA | 36 |
| BLOOD PRESSURE INCREASED | 25 |
| DIARRHOEA | 21 |
| NAUSEA | 18 |
| PALPITATIONS | 18 |
| MUSCULAR WEAKNESS | 17 |
| ASTHENIA | 16 |
| DEPRESSION | 16 |
| BLOOD CREATINE PHOSPHOKINASE INCREASED | 15 |
| RHABDOMYOLYSIS | 15 |
| ASPARTATE AMINOTRANSFERASE INCREASED | 13 |
| DIZZINESS | 13 |
| PAIN IN EXTREMITY | 13 |
| ARTHRALGIA | 12 |
| GAMMA-GLUTAMYLTRANSFERASE INCREASED | 12 |
| MYOGLOBIN BLOOD INCREASED | 12 |
| QUADRIPARESIS | 12 |
| HEADACHE | 11 |
| ACUTE KIDNEY INJURY | 10 |
| DYSPNOEA | 9 |
Nearby — Related Medications
What the FAERS Data Reveals About bempedoic acid Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 2,157 voluntary reports linked to bempedoic acid and its brand equivalents (Nexletol), spanning 2018 through 2025. Of those, 16 (0.7%) listed death as an outcome and 188 (8.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 63% were female and 37% male; age distribution skews toward 65-74, with 435 reports in that bracket. The single most reported reaction is myalgia with 335 submissions, followed by arthralgia and muscle spasms.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.